INTRODUCTION
============

Asthma is a complex disease involving a combination of genetic and environmental interactions that culminates in inflammation involving cells of the innate system enhancing the production of cytokines leading to phenotypes of bronchial hyperresponsiveness and atopy.[@B1] The global prevalence of asthma is increasing and at present, \~235 million people are suffering from this disease.[@B2] This widespread disease is characterized by increased IgE levels and airway hyperresponsiveness.[@B3]

Linkage studies have identified consistently replicated regions for asthma susceptibility on chromosomes 2q, 5q, 6p, 12q, and 13q, while other regions that have been reproducible in at least 2 populations include 1p, 2p, 3p, 4q, 7p, 11q, 16p-q, 17q, 19q, and 20p. These loci were identified in samples covering African-Americans, Hispanics, Dutch, Caucasians, Hutterites, Netherlands, German, and Swedish families.[@B4],[@B5],[@B6] Genetic studies have identified numerous genes reproducibly associated with asthma, yet these studies have focused almost entirely on single nucleotide polymorphisms (SNPs), ignoring the contribution from the other form of large variations, such as copy number variations (CNVs).[@B7] Differences between the genotypes of any 2 individuals occur mainly because of SNPs and CNVs.

Among the variations, CNVs are segments longer than 1 kb up to several Mbs, which contribute to a large number of nucleotide variations, compared to SNPs. CNVs are prone to cause instability and rearrangements leading to genomic disorders.[@B8],[@B9] Several genome-wide screenings for CNVs have demonstrated that deletions and duplications that disrupt gene functioning are more found in patients than in healthy subjects.[@B10],[@B11] The whole copy of gene sequence or partial gene sequence disruption leads to abnormalities in protein expression leading to disease manifestation.[@B12] However, copy number (CN) state of a CNV plays a significant role in determining the zygosity of alleles.[@B13] CNVs alter the genome by exon shuffling, disrupting coding sequences, modify the dosage of genes, and disturbing the regulation mechanism of gene expression. A previous study reveals the association of CNVs with asthma.[@B14] Therefore, the present study aimed to identify CNV burden on randomly selected control cohorts and to assess the prevalence of primary hit CNVs in asthma-causing genes in normal cohorts predisposing them to asthma.

MATERIALS AND METHODS
=====================

Subjects and genotyping
-----------------------

The study included a total of 1,715 individuals excluding QC-failed sample sets of the populations, involving 38 Indian samples, 269 HapMap samples, 31 Tibetan samples, 155 Chinese samples, 464 of Ashkenazi Jews (AJ) replicate I (AJ-I), 480 of AJ replicate II (AJ-II), 184 individuals from Taiwan, 53 from Australia, and 41 from New World populations (Totonacs and Bolivians), were selected for CNV analysis in the genome. The HapMap 269 individuals\' sample data from the 4 populations was obtained from the International HapMap Consortium, covering CEU (CEPH collection), CHB (Han Chinese in Beijing, China), JPT (Japanese in Tokyo, Japan), and YRI (Yoruba in Ibadan, Nigeria) populations.[@B15] The raw, unprocessed data from Affymetrix Genome Wide SNP 6.0 array for all the remaining populations except India were obtained from the ArrayExpress Archive of the European Bioinformatics Institute. The Indian study group includes the members from randomly selected 12 families residing in Karnataka, India with different age group members ranging from 13 to 73 years. EDTA blood (5 mL) was collected from each member of the Indian study group, and genomic DNA was extracted using the Promega Wizard® Genomic DNA purification kit (Promega Corporation, Madison, WI, USA). The isolated DNA was quantified by Bio-photometer and gel electrophoresis. This research was approved by the University of Mysore Institutional Human Ethics review committee (IHEC). Written informed consent was obtained from all sample donors and the IHEC approved the sample consent procedure. Written informed consent was obtained from parents/guardians in the cases of participants being minors. For genotyping, CN state algorithm calling, and data analysis, we followed the methods of Veerappa et al.[@B16]

Gene ontology and pathway analysis
----------------------------------

The selection of asthma-associated and causal genes was done through a literature survey. Genes identified under the CNVs of the study population were classified based on the biological process, molecular function, and cellular components using the EnrichR tool. EnrichR is a state-of-the-art gene set enrichment analysis, which includes application for gene-set libraries, rank-based enriched terms. EnrichR provides access to \~35 gene-set libraries, such as from the encyclopedia of DNA elements project, Epigenomics Project for histone modifications, and mouse phenotypes from the mouse genome informatics using the mammalian phenotype; structural domains; protein-protein hubs; protein complexes; kinase substrates; differentially phosphorylated proteins from the stable isotope labeling by amino acids in cell culture experiments; differentially expressed genes after approved drug perturbations; and virus-host protein interactions.[@B17]

Asthma pathway analysis was performed using WebGestalt \"WEB-based GEne SeT AnaLysis Toolkit,\" a web-based enrichment analysis tool. This tool contains an integrated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The hypergeometric statistical method with the Benjamini-Hochberg procedure was applied as a multiple test adjustment to calculate the false discovery rate (FDR) for each P value and significance level of top 10. The KEGG Pathway organizes genes based on the pathways associated with the gene set and on the number of genes in each pathway. The KEGG pathway also provides *P* values, indicating the significance of enrichment and each pathway map contains genes from the gene set that are highlighted in red.[@B18]

Breakpoint validations
----------------------

To validate some of the recurring CNVs with the break points 195276060 bp-195446910 bp on 3q29; 34695310 bp-34857998 bp on 15q14; 14594223 bp-15101046 bp on 21q11.2 and 16377650 bp-16635603 bp on 16p13.11 that were identified from this study, PCR was performed on 400 randomly chosen individuals for 4 CNV breakpoints. Chimeric primers flanking normal and deleted/duplicated sequences were designed so as to bind only to CNV breakpoint regions. Samples that do not contain these specific CNVs would fail to amplify. PCR products were analyzed by agarose gel electrophoresis. PCR amplification was performed on 2 human genomic DNA samples using DreamTaq polymerase incubated with primers at 95℃ for 3\' followed by 35 cycles of 94℃ for 30\'\', 62°-68℃ for 30\", and 72℃ for 5\' in Kyratec PCR System (Kyratec, Queensland Australia). All PCR products were analyzed on 1% agarose gels and documented with a Vilber Lourmat Imaging system (Vilber Lourmat, Marne-la-Vallée cedex France).

RESULTS
=======

Genome-wide genotyping
----------------------

We began analysis by choosing 300 genes from the genome, which were known to be associated or causal genes for asthma. CNVs in the regions of the genome containing asthma genes were identified in 17% of subjects across the study populations. These CNVs were found in individuals across all populations ranging from 3% to 68% with the highest being identified in New World populations (68%), followed by samples from Tibet (65%), Australia (42%), YRI (30%), AJ-II (28%), JPT (22%), AJ-I (20%), Taiwan (16%), CHB (16%), China (15%), India (8%), and CEU (3%). We found 8 CNV break points that were conserved across multiple populations. Among them, 6 were start break points, and 2 were end break points on chromosomes 17 and 22 encompassing chemokine (C-C motif) ligand 3-like 1 (*CCL3L1*) and glutathione S-transferase theta 1 (*GSTT1*) genes ([Fig. 1A](#F1){ref-type="fig"}). The 3 start break points \"34435512 bp\", \"34439966 bp\", and \"34443800 bp\" of CNVs encompassing *CCL3L1* gene were present in 4 populations each, and 1 start break point was present in 5 populations \"34437116 bp,\" and another was present in 6 populations \"34528113 bp\". Similarly, 1 start break point \"24283004 bp\" encompassing *GSTT1* gene was present in 4 populations. An end break point \"24396802 bp\" with *GSTT1* gene was present in 8 populations, and the other end break point \"34629684 bp\" embedding *CCL3L1* gene was present in all the study populations. The populations AJ-I and AJ-II were considered 1 population; similarly, China and CHB were considered 1 population for this analysis because they arise from the same country.

Of the total 44,109 CNVs identified from 1,715 individuals, 61 singleton asthma genes were found in many individuals. These 61 genes were the singleton number of genes from 401 (includes number of same genes repeated in different individuals) genes of 294 individuals and 368 CNVs across 12 populations. Asthma genes were overembodied in duplication regions (72%) compared to deletion regions (28%) and were also distributed across populations in varying concentrations. Out of 61 asthma genes, 10 occurred in higher percentages (above 1%) among study populations; *CCL3L1* was highest, followed by ADAM metallopeptidase domain 8 (*ADAM8*) and mucin 5B, oligomeric mucus/gel-forming (*MUC5B*) genes ([Fig. 1B](#F1){ref-type="fig"}).

The 368 asthma-CNVs were found with an average size of 338 kb ranging from 100 to 425 kb. Variations were observed in almost all chromosomes except in 15, 18, 20, 21, and Y, and these variations were identified by \~14,000 combined SNP and CNV markers. [Fig. 2](#F2){ref-type="fig"} shows the singleton genes found in all 12 populations distributed in chromosomes 1-14, 16-17, 19, 22, and X. Among them, a cluster of asthma genes were embedded on chromosomes 5q, 6p, 10q, and 17q.

CNVs encompassed asthma genes both completely and partially across many genome regions; however, out of the 368 encompassing CNVs identified, \~78.66% were complete gene duplications/deletions, while \~21.33% partially truncated the coding structure. The CN state across these CNVs ranged from CN=0 to CN=4. CN state 3 was found at 60% (the highest prevalence), followed by CN=1 at 24.31%, CN=4 at 10.17%, and CN=0 at 3.22%.

[Table 1](#T1){ref-type="table"} depicts the number and percentage of duplication and deletion frequency of 3 frequently occurring asthma genes under CNVs in all the populations under study. The expression levels of proteins were analyzed using the database of EBI (The European Bioinformatics Institute) expression atlas, which has baseline expression data. *CCL3L1* showed a value of 0.7 in the lungs where the expression level breakdown for *CCL3L1* is 1 out of 4 transcripts. CN=0 was the complete loss of protein, the CN=1 showing the dosage level of *CCL3L1* protein was 0.35, CN=3 showed the expression level of 1.05, and CN=4 was present in 30 individuals with a protein level expression of 1.4 ([Table 2](#T2){ref-type="table"}). Similarly, *ADAM8* showed the value of 8 with expression of 2 transcripts out of 11. This gene was under the burden of 2 types of CN states 0 and 3; among them CN=0 was complete loss of expression of this protein, and CN=3 was in 2 types of burden with 34 individuals carrying complete intact gene duplication with a dosage level of 12, but the remaining 46 individuals carried partial duplication of *ADAM8* gene which showed a protein level of 4. Likewise, *MUC5B* showed a value of 15 by expressing 3 transcripts in the lungs out of 6 transcripts. This gene was under duplication burden with only 2 types of CN states 3 and 4, and all CNVs encompassed complete gene duplication. CN=3 showed a dosage level of 22.5, and CN=4 was present in 4 subjects with a dosage level of 30.

Interestingly, we also identified 67 individuals bearing multiple asthma genes under the influence of CNVs with varying CN states with either or sometimes both intact/partial CNV overlaps. CNVs that occurred with an overall frequency of less than 1% in the general population were defined as \'rare CNVs,\' whereas those which were above 5% were reffered as \'common CNVs.\' Asthma CNVs were both common and rare in occurrence when checked against the online database of genomic variants; further, common CNVs (91%) were highly prevalent than rare CNVs (9%). The AJ population showing the highest occurrence for common CNVs at 34%, while India and New World populations showing the highest occurrence (8%) of rare CNVs across all populations. CNV overlaps were encompassing genes either completely or partially across genomes of all populations. CNVs completely encompassing genes resulting in intact promoter and coding structure duplication/deletions were significantly higher (79%) compared to CNVs disrupting coding structure partially (21%). In addition, the CNV regions were further investigated to classify them as novel regions and breakpoints based on the CNV location and size. We identified 47 novel regions across the genome, which contained CNVs, not reported earlier in the database of genomic variants (<http://dgv.tcag.ca/dgv/app/home>), and also we identified 7 novel breakpoints in the recurrent CNV regions. These variations are now available in University of Mysore Genome Centre database (<http://umgc.uni-mysore.ac.in>). Novel regions and breakpoints were higher than novel breakpoints alone, with New World and Australia showing 15 and 12 novel regions and breakpoints, respectively. Meanwhile, HapMap, AJ-I, and Indian populations showed no CNVs in the novel regions bearing asthma genes.

Sex bias and inheritance in asthma genes under CNVs
---------------------------------------------------

CNVs in asthma genes were observed to be biased in male and female genomes in several populations ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). For inherited CNVs, we recognized 7 CNVs that were being inherited from parents to offspring. For this analysis, we used 3 populations, YRI, CEU, and India whose trio family data were available. YRI, with 30 children from 30 trio families were found with 7 CNVs encompassing asthma genes that were being inherited from the parents, while CEU and Indian populations did not contain inherited CNVs. All the 7 inheriting asthma CNVs were duplicative CNVs with both CN states 3 and 4. Five CNVs among them were being paternally inherited, while 2 were being maternally inherited.

Categorization of asthma genes
------------------------------

The identified 61 singleton genes were further divided into 3 major categories based on biological processes, molecular function, and cellular location using the EnrichR gene enrichment analysis tool. In biological processes, a majority of asthma genes were encoded for responses to external stimuli, responses to wound, and inflammatory/defense responses ([Fig. 3A](#F3){ref-type="fig"}). Similarly, in the molecular function category, a majority of asthma genes were identified under signal transducer, receptor-binding, and growth factor activities ([Fig. 3B](#F3){ref-type="fig"}), while under the cellular components the genes were coded for proteins that were located in the regions of extracellular space, integral to the plasma membrane and extracellular region ([Fig. 3C](#F3){ref-type="fig"}).

Disease gene enrichment
-----------------------

We examined identified genes to determine functional relevance and disease pathways relevant to asthma. [Fig. 4A](#F4){ref-type="fig"} indicates the functional enrichment of pathways using the identified asthma-CNV genes. The top \>20 ranked categories included functional and disease categories related to the FC-Epsilon-RI signaling pathway, and pathways for MHCII and eotaxin. These genes in these pathways, if altered, may result in asthma development. [Supplementary Table 2](#S2){ref-type="supplementary-material"} represents the function of genes with their common break points and CN states under study populations.

Genes of similar functional groups are expected to be enriched for gene ontology (Panther Classification and GORILLA annotations), share the same pathways (WikiPathways, KEGG and Pathway Commons), enabling the integrated use of these systems to establish biological, molecular, and cellular pathways based on the genes enriched in CNVs. Though the genes identified under this study were significantly enriched for asthma, they also overlapped among genes in both related and unrelated disorders. The statistical analysis to score gene enrichment on the pathway map revealed varying enrichment according to diseases. The genes identified in the study were enriched significantly for asthma, lung cancer, anemia, leukemia, diabetes, and myocardial infarction, indicating significant overlaps between genes for these diseases ([Fig. 4B](#F4){ref-type="fig"}).

DISCUSSION
==========

CNV burden on asthma genes
--------------------------

Organizational deviations that are generally occurring in the genome of individuals are CNVs. These variations occur in 2 forms, duplications and deletions conferring predominant variability than that of SNPs, inDels or chromosomal rearrangements. Large segmental duplications are presumed to be the root for CNVs, which are observed to be associated with diseases.[@B7],[@B19] The influence of CNV on asthma is comparatively less studied, but recent evidence strongly confirms the causality of asthma genes due to CNVs.[@B20]

In the present study, genes under duplicated CNVs were higher than those under deletion CNVs. Diseases have been shown to occur due to excess copy of dosage-sensitive genes and also by loss of gene function due to deletions.[@B11] We assume that the genome can withstand more duplication than deletion, as deletions can be more harmful to the function and organization of the genome. A higher duplication state of the asthma genes indicates the role of high dosage of proteins playing a significant role towards the etiology of asthma pathogenesis. Similarly, CNVs completely encompassing the coding structure along with an intact promoter were found to be significantly higher compared to CNVs disrupting coding structure partially. The complete or partial CNVs in genes may affect transcription rates dynamically along with the effect on binding capacity of themselves along with other genes indirectly[@B21] leading to disease manifestation. The presence of asthma genes under common CNVs compared to rare signifies the prevailing heavy burden of asthma CNVs in normal cohorts, indicating the presence of a latent period before being triggered by other notable variations making individuals more prone by providing a stronger effect on the phenotype leading to asthma pathogenesis.[@B22],[@B23]

We came across 8 CNV breakpoints that are conserved in many populations in which highly frequent CNV embedding *CCL3L1* has been selected to be under such conserving mechanism, YRI population being the point of origin of human evolution[@B24] is carrying more of the conserved CNV breakpoints. Therefore, these CNVs could persist for a long period of time and probably expand to acquire further aberrations in encompassing gene or any other gene that falls under the same disease pathway.

These asthma genes are under the influence of CNVs, with varying CN states ([Supplementary Table 1](#S1){ref-type="supplementary-material"}), which is one of the deciding factors, for the expression level of a protein. Ten genes were present at a frequency of \>1% among the study populations. One of the highly abundant genes obtained in the study, *CCL3L1* is under the influence of CN states-0, 1, 3, and 4. This is a chemokine and a potent regulator of inflammation, immune responses, and allergy. This gene was highest under CNVs at 28.92% with varying values of protein dosage level due to influence of different types of CN states. In AJ-I and AJ-II, out of 37 CNVs encompassing *CCL3L1* gene, 31 were with CN state 1, 1 CNV with CN state 0 and the remaining 5 CNVs were with CN state 3. However, in YRI population, out of 23 CNVs, 13 were with CN state 3, and 4 CNVs were with CN state 4. The low level expression of *CCL3L1* protein due to CN state 0 and 1 is associated with asthma.[@B25] This result might help to provide one of the answers for the reason towards the susceptibility to asthma in AJ-I and AJ-II (Germany) populations compared to YRI (Nigeria). The prevalence of asthma in Nigeria is less compared to Germany.[@B26] *CCL3L1* acts by up-regulating the expression of an anti-inflammatory cytokine IL-10 in a dose dependent way, which in turn acts as a negative regulator of Th2 allergic responses during asthma pathogenesis.[@B25] The normal level of 0.7 of *CCL3L1* is required to regulate the normal level of IL-10, which is 0.5. In case of deletion in *CCL3L1* with CN=1, the dosage level will be 0.35 which can regulate expression of only 0.25 level of IL-10 and hence the remaining 0.25 level of IL-10 is not expressed to keep up the normal level of IL-10. Hence, this low level of expression of IL-10 increases the incidence of asthma in individuals bearing deletion of *CCL3L1* with CN=1. CNVs have been found in *CCL3L1* in families with asthma,[@B27] while deletion CNVs have been associated with asthma where the low level expression of *CCL3L1* impacts the risk of asthma by modulating IL-10 expression. However, a high copy number of ≥5 is associated with decreased asthma risk. Subjects with ≤1 copy of *CCL3L1* have significantly lower mRNA levels of *CCL3L1* in peripheral blood cells and significantly higher serum IgE levels.[@B25]

*ADAM8*, which is present at a frequency of 20.19%, is a member of the disintegrin and metalloproteinase family of genes, which is high when IL-4 or IL-13 levels are increased during increased allergen-induced airway hyperresponsiveness. *ADAM8* is present under CN=1 and 3 but CN=3 is in 2 forms because some individuals carry complete duplication of genes and others with partial duplication. The duplication of partial genes impacts the protein level expression in a reverse way by reducing the protein dosage rather than increasing it. However, in duplication of intact genes with CN=3, the dosage level will be 12 which is high compared to normal level of 8, thus in this duplicated level it might lead to airway hyperresponsiveness. *ADAM8* gene might participate in the interplay of allergic responses with its member family genes like *ADAM33*.[@B28] *ADAM33* is a known candidate gene for the pathogenesis of asthma, even though the exact mechanism of interplay of this gene is not yet understood clearly but it is found to interact with multiple genes to manifest the disease.[@B29],[@B30] Paulissen et al.[@B31] have shown recruitment of dendritic cells of the lung by *ADAM8* and its overexpression leading to the production of *CCL11* and *CCL22* due to allergen exposure aiding in acute airway inflammation in asthma. Allergic asthma may also be a result of *ADAM8* deregulation leading to regulatory modulation of *PSGL-1* altering the expression and activation of ADAM8 during leukocyte extravasation.[@B32] Previous studies have identified few SNPs in the *ADAM8* to confer protection against allergic asthma and atopy.[@B33] However, SNP associations in *ADAM8* for asthma and atopy are found to be modest in magnitude.

Similarly, the next highest gene highest is *MUC5B*, which has 2 types of CN states 3 and 4, all being complete and intact gene duplications. Hence, there is a presence of high dosage level of this protein. *MUC5B* represents the 10.72% among the genes under the study, which is a mucin that produces mucous in small airways of the lungs and thus is involved in functional homeostatic clearance.[@B34] With all the CNV embedding intact genes, the dosage level will be 22.5 with CN=3 and 30 with CN=4 compared to the normal level of 15. In both conditions, mucous secretion will be too high which might lead to airway thickness. These frequently occurring asthma genes can be used as biomarkers for early detection of susceptible individuals. These expression levels do not depend only on the burden of CNVs. However, CNVs may also significantly influence expression levels of these proteins. *MUC5B* contributes to a phenotype of distinct mucus hyper-secretion. Overexpression of *MUC5B* have been observed in asthma secretions, where a large volumes of *MUC5B* protein (form of mucus plugs) has been found in airway lumen, necks of glandular secretory ducts and in the lining of lung epithelia.[@B35],[@B36] The reasons for such overexpression have been mainly implicated on the presence of rare variants of *MUC5B* which operate by interacting with small amounts of *MUC2* glycoprotein to produce mucin gel.[@B37]

We could notice 4 clusters of genes embedding on 5q, 6p, 10q, and 17q under CNV in this study. In multiple studies, 5q, 6p, and 17q are reported but 10q is less frequently associated.[@B4] We also observed more than 1 asthma-CNV event in 67 individuals. There might be an increase in chances for the susceptibility to complex diseases upon exposure to environmental pollutants and multiple mutation incidences.[@B38] Therefore, it can be predicted that the second hit of susceptible CNV in a person with preexisting susceptibility CNV makes the individual more prone to asthma.

Sex bias and inheritance in asthma genes under CNVs
---------------------------------------------------

We noticed some of the genes that are only in males of certain population and some only in females. However, these genes cannot be concluded to be gender- specific as in other populations showing balanced occurrences in both genders. As the sample size available in the present study is statistically insignificant, further studies are required to understand this phenomenon.

Studying the inheritance pattern revealed that CNVs encompassing asthma genes were inherited only in the YRI population with a frequency of 26%. We also found some asthma CNVs exhibiting the phenomenon of 1 breakpoint precisely were inherited, while the other break point was being slightly extended in the next generation, which was referred as \"unknown\" category of CNV inheritance.[@B13] Previous studies indicted diverse CNV transmissions along with *de novo* event rates in probands for several neurodevelopmental phenotypes and monozygotic twin studies.[@B39],[@B40],[@B41] Though the asthma CNV inheritance rate is comparatively lower than *de novo*, the role of inherited asthma CNVs towards CNV burden cannot be discounted. The \"unknown\" type of inheritance pattern may lead to the extension of sequences under CNVs in future generations and might cause more of gene sequences to be under CN burden. Hence, such kinds of CNV inheritance patterns are yet to be comprehended clearly to know the pathogenesis of diseases. There might also be presence of latent period in an individual who has susceptible asthma CNV that might be inherited from previous generations and due to second hit of susceptible CNV mutation or the extension of sequences of preexisting CNV might lead to manifestation of asthma.

Categorization of asthma genes
------------------------------

The identified asthma genes under CNV burden, which are subjected to enrichment analysis, revealed that, of the 61 genes under the biological process, majority were under the process of external stimulus followed by wounding, inflammatory, defense and immune responses. Under the cellular component, a majority of them were present in the extracellular space while some were found in various cellular locations, indicating that asthma-associated genes are not regionally specific and not biased in their location. Similarly, under the molecular function, more genes were found to participate in signal transducer activity, receptor binding, chemokine activity, and cytokine activity. Asthma depicts airway obstruction and wheezing episodes, which are the after-effects of chronic inflammation and airway narrowing. Inflammation is intensified by external stimuli and responses of smooth muscles, epithelial cells, and fibroblasts by producing different kinds of cytokines, chemokines, and proteases.[@B42]

Disease gene enrichment
-----------------------

There are several implicative signaling pathways for asthma disease pathogenesis. Asthma CNVs we found in the present study are involved in the FC-Epsilon-RI signaling pathway, antigen processing and presentation (MHCII), and pathway for eotaxin. The FC-Epsilon-RI signaling pathway is important to maintain the mast cell levels which are the principal component of hypersensitivity reaction.[@B43] Antigen presenting and processing is also important in immune responses. The macrophage, which is an antigen-presenting cell, utilizes cell adhesion molecules to bind to T-cells where T-cell responses are crucial in the pathogenesis of asthma.[@B44] Pathways, including mechanisms of eotaxin, are important for the recruitment of eosinophils to the location of allergic inflammation,[@B45] where eosinophils are involved in inflammation of the lungs leading to bronchial hyperresponsiveness in case of asthma.[@B46]

The genes obtained in the study are significantly enriched for multiple diseases mainly for asthma followed by malaria, different types of cancers, myocardial infarction, diabetes, leukemia, anemia, migrane, alzheimer, immunodeficiency, schizophrenia, dementia, and Zellweger syndrome. This signifies that the role of CNVs burden on genes causing various types of complex disorders. These human disorders by occurring in such kind of disease network shows that they are causing due to genes of similar genetic origin and molecular function.[@B47]

Asthma is a complex disease, and its trigger is based on the susceptibility present in the genome of an individual towards environmental factors. This study helps design markers for the identification of susceptible individuals, as asthma cannot be identified unless and until the disease is manifested. CNVs alone may not be the reason for the manifestation of asthma, and the additional environmental factors or mutations may be required for the occurrence of asthma. Therefore, this study helps reveal CNV burden with varying CN states on normal cohort genome carried out in different geographical areas of the world and the relevance of the observation with respect to disease CNV burden, frequency, etiology, and pathogenesis of asthma.

Diseases have been shown to occur due to either excess or lack of copies of dosage-sensitive genes and also by loss of gene function due to deletions.[@B11] A varying CN states of the asthma genes (ex: *MUC5B* in case of higher dosage and *CCL3L1* in case of lower dosage) indicates the role of protein dosage playing a significant role in asthma pathogenesis. Since persons affected with deletion CNVs are more likely to have additional large CN variants than controls. The secondary CNVs are known to be associated with variable sets of outcomes, ranging from neuropsychiatric diseases to severe intellectual disability to certain autoimmune conditions and rare CN variants that are potentially pathogenic.[@B48],[@B49],[@B50] Therefore, the present study was to identify the prevalence of primary hit CNVs in asthma-causing gene in normal cohorts predisposing them to asthma. It can be hypothesized that primary CNVs may not be the initiating event in the pathogenesis of asthma and additional preceding mutations or CNVs may be required. The initiator or primary CNVs sensitize the normal cohorts, leading to an increased probability of accumulating mutations or exposure to allergic stimulating agents that can augment the development of asthma.
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###### Frequency of asthma genes under CNVs in males and females of study population

![](aair-7-265-s001)

  Gene        YRI   CEU   AJ I   AJ II   CHB   China   Tibet   India   JPT   Australia   New world   Taiwan                                                              
  ----------- ----- ----- ------ ------- ----- ------- ------- ------- ----- ----------- ----------- -------- ------ ---- ----- --- ----- ---- ----- ------ ------ ----- -----
  ACAA1                                                                                                                                                            1.0   
  ACE                                                  0.4                                                                                                               
  ADAM8       1.8                        3.8   5.3     8.5     7.4                                            18.2   15                              5.2           6.5   8.6
  AICDA                                  0.4           0.4                                                                                                               
  ALOX5                                        0.4                                                                                                                       
  BDNF                                                                                                        9.0                                                        
  C14orf180                                                                                                                                    3                         
  C5orf56                                                                                                                                                   2.4          
  CCL11                                        0.4             0.4                                                                                                       
  CCL2                                         0.4             0.4                                                                                                       
  CCR1                                                                                                                                                      4.8          
  CCL3L1      23    30    5      2       3     2       5       5       14    5           11          7        55     10         5   13    23   6            2      4     50
  CD69                                                                                                                                                      2.4          
  CDK2                                                         0.4                                                                                                       
  CHRM3                                                                      4.5                                                               6                         
  CSF2                                                         0.4                                                                                                       
  CTNNA3                                 0.8   0.4                                                   1.3                                                                 
  CXCL12                                       0.8                                                                                        3    5.2                       
  CYSLTR1                                      0.4                                                                                                                       
  DIAPH3                                 0.4                                                                                                                             
  DPP10                                                                      4.5                                                                                         
  EGFR                                                         0.4                                                                                                       
  GPX3                                                         0.8                                                                                                       
  GSTCD                                  0.4                                                                                                                             
  GSTT1       3.7   2.7                  0.8   0.4     1.2     1.2           4.5         7.5         1.3             5    5.5       8.6              5.2    2.4          
  HAVCR1                                 0.4                                                                                                                             
  HAVCR2                                 0.4                                                                                                                             
  HLA-DQA1                                     0.4                                                                                                                       
  HLA-DRA                                                                                                                                            5.2                 
  HLA-DRB1                                     0.4             0.4                                            9.0    5                               5.2                 
  HLA-DRB5                                     0.8             0.4                                            9.0    5                               15.7                
  ICAM1                                                                                              1.3                                                                 
  IL13RA2                                2.5   2.2     1.7     1.2                                                                                                       
  IL17RB                                       0.4             0.4                                                                                                       
  IL1A                                                                                                                                                      12.1         
  IL1B                                                                                                                                                      12.1         
  IL3                                                          0.4                                                                                                       
  IL33                                                         0.4                                                                                                       
  IL4R                                                                                                                                                      2.4          
  IL8                                                                                                                                                       7.3          
  IL9                                                                                                                                          3                         
  IRF1                                                                                                                                                      2.4          
  KCNIP4                                 0.8   0.4             0.4                                                                                                       
  LTA                                                                                                                                                       4.8          
  MBL2                                   0.4                                                                                                                             
  MUC2                                   0.8   1.3     2.9     2.0                                                                                                       
  MUC5B                                  3.3   2.2     8.1     3.7                                                                                                       
  NQO1                                   0.4                                                                                                                             
  NRG1                                                                                                               5    5.5                                            
  OPN3                                   0.4                   0.4                                                                                                       
  PIM1                                                                                               1.3                                                                 
  PRKG1                                  0.4                                                                                                                             
  PTGER2                                               0.4                                                                                                               
  STAT3                                                                                                                                                     4.8          
  TBXA2R                                                       0.4                                                                                                       
  TIMP3                                                                                                                                        3                         
  TLR2                                                         0.4                                                                                                       
  TNF                                                                                                                                                       4.8          
  TNFAIP3                                                                                                                                                   2.4          
  TNS1                                                                                                                                         9     10.5                
  ZNF618                                                                                                                                             5.2                 

###### CNVs identified with asthma associated genes with their chromosomal location, break-points, CN states and gene functions

![](aair-7-265-s002)

  Gene        Chromosome location   Break-point (bp)      CN state   Gene function
  ----------- --------------------- --------------------- ---------- -------------------------------------------------------------
  ACAA1       3p22.2                38039344-38185174     3          Acetyl-coA C-acyltransferase activity
  ACE         17q23.3               61518220-61624537     3          Actin binding
  ADAM8       10q26.3               135056464-135174110   0, 3       Metalloendopeptidase activity
  AICDA       12p13.31              8529380-8763073       1          Cytidinedeaminase activity
  ALOX5       10q11.21              45827177-45940122     3          Arachidonate 5-lipoxygenase activity
  BDNF        11p14.1               27636885-27789198     3          Growth factor activity
  C14orf180   14q32.33              104938308-105067722   3          \-
  C5orf56     5q31.1                131721749-131825114   1          \-
  CCL11       17q12                 31953738-32936539     3          Chemokine activity
  CCL2        17q12                 31957151-32938022     3          Chemokine activity
  CCR1        3p21.31               46129533-46281822     1          Chemokine receptor activity
  CCL3L1      17q12                 34437116-34629684     0,1,3,4    Chemotactic for lymphocytes and monocytes
  CD69        12p13.31              9879084-9993452       1          Transmembrane signaling receptor activity
  CDK2        12q13.2               56297625-56413629     3          Cyclin-dependent protein serine/threonine kinase activity
  CHRM3       1q43                  239917246-240298870   3          G-protein coupled acetylcholine receptor activity
  CSF2        5q31.1                131317464-131419202   3          Cytokine and growth factor activity
  CTNNA3      10q21.3               68367662-68515140     1, 3       Cadherin binding
  CXCL12      10q11.21              44860013-44975407     3          Cytokine and growth factor activity
  CYSLTR1     Xq21.1                77513603-77753914     3          Leukotriene receptor activity
  DIAPH3      13q21.2               60204504-60381540     1          Rho gtpase binding
  DPP10       2q14.1                116532508-116675350   3          Serine-type peptidase activity
  EGFR        7p11.2                55126900-55245507     3          Epidermal growth factor-activated receptor activity
  GPX3        5q33.1                150399114-150513847   3          Glutathione peroxidase activity
  GSTCD       4q24                  106447752-106760931   1          \-
  GSTT1       22q11.23              24288422-24396802     0- 4       Glutathione peroxidase activity
  HAVCR1      5q33.3                156409111-156564456   3          \-
  HAVCR2      5q33.3                156409111-156564456   3          \-
  HLA-DQA1    6p21.32               32456671-32625083     1          T cell receptor signaling pathway
  HLA-DRA     6p21.32               32408527-32530286     4          T cell receptor signaling pathway
  HLA-DRB1    6p21.32               32456671-32625083     1, 4       Peptide antigen binding
  HLA-DRB5    6p21.32               32429894-32530286     1, 4       Peptide antigen binding
  ICAM1       19p13.2               10369086-10471048     1          Transmembrane signaling receptor activity
  IL13RA2     Xq23                  114205618-114397728   2, 3       Cytokine receptor activity
  IL17RB      3p21.1                53775447-53890848     3          Cytokine receptor activity
  IL1A        2q13                  113500222-113644927   1          Cytokine activity
  IL1B        2q13                  113512866-113644927   1          Cytokine activity
  IL3         5q31.1                131317464-131419202   3          Cytokine activity
  IL33        9p24.1                6121448-6256144       1          Cytokine activity
  IL4R        16p12.1               27251081-27377242     1          Interleukin-4 receptor activity
  IL8         4q13.3                74567500-74758477     1          Chemokine activity
  IL9         5q31.1                135123627-135231195   3          Cytokine activity
  IRF1        5q31.1                131721749-131825114   1          Sequence-specific DNA binding transcription factor activity
  KCNIP4      4p15.2                21637793-21740358     3          Voltage-gated ion channel activity
  LTA         6p21.33               31474688-31595882     1          Cytokine activity
  MBL2        10q21.1               53511985-57787459     1          Calcium-dependent protein binding
  MUC2        11p15.5               1073860-1332223       3          Protein binding
  MUC5B       11p15.5               1150425-1291777       3, 4       Extracellular matrix structural constituent
  NQO1        16q22.1               68860698-69771914     1          NAD(P)H dehydrogenase (quinone) activity
  NRG1        8p12                  32422268-32522771     3          Cytokine and growth factor activity
  OPN3        1q43                  241099314-242090693   3          G-protein coupled receptor activity
  PIM1        6p21.2                37130282-37236436     3          Protein serine/threonine kinase activity
  PRKG1       10q21.1               53511985-57787459     1          Calcium channel regulator activity
  PTGER2      14q22.1               52788759-52902018     1          Prostaglandin E receptor activity
  STAT3       17q21.2               40498189-40608285     1          Transcription regulatory region DNA binding
  TBXA2R      19p13.3               3554783-3700847       3          Guanyl-nucleotide exchange factor activity
  TIMP3       22q12.3               33142908-33251959     3          Metalloendopeptidase inhibitor activity
  TLR2        4q31.3                154515618-154825256   3          Transmembrane signaling receptor activity
  TNF         6p21.33               31480272-31654732     1          Cytokine activity
  TNFAIP3     6q23.3                138092422-138206150   1          Ubiquitin-specific protease activity
  TNS1        2q35                  218600074-218709313   3          Actin and protein binding
  ZNF618      9q32                  116811184-116930194   3          DNA binding

![(A) Conserved CNV break points among the study populations. Figs. A to F represent conserved start break points, and G-H represents conserved end break points. The start break points A- 34435512, B- 34439966, C- 34443800, D- 34437116, and E- 34528113 encompass *CCL3L1* gene, and F- 24283004 encompasses *GSTT1* gene. Similarly, the end break point G- 24396802 encompasses *GSTT1* gene, and H- 34629684 encompasses *CCL3L1* gene. (B) Distribution of frequency of genes obtained in the study populations. The highest percentage is observed in *CCL3L1*, followed by *ADAM8*, *MUC5B*, *GSTT1*, *IL13RA2*, and *MUC2* in decreasing order, and the genes with frequency \<2% are represented in a single slot.](aair-7-265-g001){#F1}

![Karyogram indicating asthma genes in the study populations. It shows that 5q, 6p, 10q, and 17q regions are embedded with a higher percentage of asthma genes.](aair-7-265-g002){#F2}

![Enrichment of asthma genes in the study populations. (A) Representation of genes under the biological process with *P* values. (B) Representation of genes under molecular function with *P* values. (C) Representation of genes under cellular components with *P* values.](aair-7-265-g003){#F3}

![Representation of enrichment analysis. (A) Functional enrichment of the pathways in the study under the KEGG pathway for asthma. (B) CNV-asthma genes enriched for other diseases.](aair-7-265-g004){#F4}

###### 

Duplication and deletion frequency of frequently occurring asthma genes under CNVs in 12 populations

![](aair-7-265-i001)

  Population          Individuals assessed   CCL3L1       ADAM8       MUC5B                               
  ------------------- ---------------------- ------------ ----------- ----------- ---------- ------------ ----
  HapMap-YRI-Africa   90                     23 (25.5%)   \-          \-          1 (1.1%)   \-           \-
  HapMap-CEU-Europe   90                     \-           3 (3.3%)    \-          \-         \-           \-
  Ashkenazi Jews I    464                    3 (0.64%)    9 (0.19%)   22 (4.7%)   \-         13 (2.8%)    \-
  Ashkenazi Jews II   480                    2 (0.4%)     23 (4.7%)   38 (7.9%)   \-         29 (6.04%)   \-
  HapMap-CHB-China    44                     4 (9.09%)    \-          \-          \-         \-           \-
  China               155                    13 (8.3%)    1 (0.64%)   \-          \-         \-           \-
  Tibet               31                     7 (22.5%)    1 (3.2%)    5 (16.1%)   \-         \-           \-
  India               38                     1 (2.6%)     \-          \-          \-         \-           \-
  HapMap-JPT-Japan    45                     8 (17.7%)    \-          \-          \-         \-           \-
  Australia           53                     1 (1.8%)     1 (1.8%)    1 (1.8%)    \-         1 (1.8%)     \-
  New world           41                     1 (2.4%)     \-          \-          \-         \-           \-
  Taiwan              184                    8 (4.3%)     7 (3.8%)    14 (7.6%)   \-         \-           \-

CNV, copy number variation.

###### 

Impact of CNV type, copy number , and overlapping status on the protein dosage level of frequently occurring asthma genes with a cutoff value of 0.5

![](aair-7-265-i002)

  Gene with baseline expression dosage in lungs   CNV type      Copy number   Number of subjects   Intact/partial   Protein dosage
  ----------------------------------------------- ------------- ------------- -------------------- ---------------- ----------------
  CCL3L1 - 0.7                                    Deletion      0             1                    Intact           0
  Deletion                                        1             44            Intact               0.35             
  Duplication                                     3             41            Intact               1.05             
  Duplication                                     4             30            Intact               1.4              
  ADAM8 - 8                                       Deletion      0             1                    Intact           0
  Duplication                                     3             34            Intact               12               
  Duplication                                     3             46            Partial              4                
  MUC5B - 15                                      Duplication   3             39                   Intact           22.5
  Duplication                                     4             4             Intact               30               

CNV, copy number variation.
